These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2980269)

  • 21. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of anti-factor VIII antibodies.
    Blatt PM; White GC; McMillan CW; Roberts HR
    Thromb Haemost; 1977 Aug; 38(2):514-23. PubMed ID: 579493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of current knowledge to the management of bleeding events during immune tolerance induction.
    Di Paola J; Aledort L; Britton H; Carcao M; Grabowski E; Hutter J; Journeycake J; Kempton C; Leissinger C
    Haemophilia; 2006 Nov; 12(6):591-7. PubMed ID: 17083508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
    Iorio A; Matino D; D'Amico R; Makris M
    Cochrane Database Syst Rev; 2010 Aug; (8):CD004449. PubMed ID: 20687076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.
    Mannucci PM; Franchini M
    Blood Transfus; 2017 Jul; 15(4):365-368. PubMed ID: 27483484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of factor VIII inhibitors.
    Acharya SS; DiMichele DM
    Best Pract Res Clin Haematol; 2006; 19(1):51-66. PubMed ID: 16377541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives.
    Ananyeva NM; Lacroix-Desmazes S; Hauser CA; Shima M; Ovanesov MV; Khrenov AV; Saenko EL
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):109-24. PubMed ID: 15090997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lingual hemorrhage in a patient with hemophilia A complicated by a high titer inhibitor. Management by continuous infusion of monoclonal antibody-purified factor VIII.
    Gordon EM; Mungo R; Goldsmith JC
    Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):107-10. PubMed ID: 8447550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postpartum acquired hemophilia (factor VIII inhibitors): a case report and review of the literature.
    Shobeiri SA; West EC; Kahn MJ; Nolan TE
    Obstet Gynecol Surv; 2000 Dec; 55(12):729-37. PubMed ID: 11128909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies.
    Gatti L; Mannucci PM
    Thromb Haemost; 1984 Jul; 51(3):379-84. PubMed ID: 6437005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Manifestations of factor VIII inhibitor in the head and neck.
    DellaCroce FJ; Kountakis S; Aguilar EF
    Arch Otolaryngol Head Neck Surg; 1999 Nov; 125(11):1258-61. PubMed ID: 10555699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquired factor VIII inhibitors in nonhemophilic patients.
    Söhngen D; Specker C; Bach D; Kuntz BM; Burk M; Aul C; Kobbe G; Heyll A; Hollmig KA; Schneider W
    Ann Hematol; 1997 Feb; 74(2):89-93. PubMed ID: 9063379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors.
    Tarantino M; Aledort L
    Transfusion; 2001 Dec; 41(12):1628-9. PubMed ID: 11778084
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment options for bleeding episodes in patients undergoing immune tolerance therapy.
    Manno CS
    Haemophilia; 1999 Sep; 5 Suppl 3():33-41. PubMed ID: 10597386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitors in haemophilia A: current management and open issues.
    Haya S; Moret A; Cid AR; Cortina V; Casaña P; Cabrera N; Aznar JA
    Haemophilia; 2007 Dec; 13 Suppl 5():52-60. PubMed ID: 18078398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM; Berntorp E
    Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
    [No Abstract]   [Full Text] [Related]  

  • 38. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
    Holme PA; Brosstad F; Tjønnfjord GE
    Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for inhibitor treatment and costs in the short and long term: a critical evaluation of recent clinical studies.
    Baghaipour MR; Steen Carlsson K
    Eur J Haematol; 2015 Feb; 94 Suppl 77():30-7. PubMed ID: 25560792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of porcine factor VIII in the management of unexpected bleeding episodes.
    Aledort LM
    Haemophilia; 2002 Jan; 8 Suppl 1():17-9; discussion 28-32. PubMed ID: 11882078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.